Presentation Information
[P-56]スクアレンベースアジュバントA-910823の有効性と副反応の誘導メカニズム
*Anri Yoshioka1, Yuya Yoshioka1, Kouji Kobiyama2, Tomoya Hayashi2, Yujiro Kidani1, Yosuke Yanagida3, Junpei Kasahara3, Yoshiji Asaoka4, Akimasa Yoshimura1, Satoru Ishida1, Shinya Omoto1, Morio Nagira1, Cevayir Coban5, Ken J Ishii2 (1. Vaccine R&D Laboratory, Shionogi & Co., Ltd., 2. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT), 3. Vaccine Manufacturing Technology Research Laboratory, Shionogi & Co., Ltd., 4. Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd., 5. Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT))